{'fraction_non_alphanumeric': 0.03607937462417318, 'fraction_numerical': 0.039085989176187615, 'mean_word_length': 5.351145038167939, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Disposition of alfentanil in patients receiving a renal transplant

The disposition of alfentanil has been investigated in 10 anaesthetized patients with chronic renal failure undergoing kidney transplantation and compared with eight age matched anaesthetized patients with normal renal function. Plasma samples were collected to 660 min following intravenous administration of alfentanil 3–5 mg (50 μg kg−1). Drug concentrations were measured by RIA; and alfentanil binding to plasma proteins by equilibrium dialysis against 0·1 M phosphate buffer, pH 7·4. Alfentanil binding to plasma proteins was 87·6% (s.d. 2·0) in the patients with chronic renal failure, and 89·7% (1·2) in patients with normal renal function (P = 0·025). There was no correlation between alfentanil binding and plasma albumin, total plasma proteins, plasma urea or plasma creatinine concentrations. In both groups, the drug concentration‐time profile decayed in a curvilinear manner; in the chronic renal failure patients, restoration of function did not influence the decay profile. Elimination half life, mean residence time and apparent volume of distribution at steady state were not different in the two groups of patients (mean values: 142·4 and 120·2 min; 128·5 and 136·0 min; and 40·5 and 27·6 L, respectively in chronic renal failure patients and patients with normal renal function). Total drug clearance and Vd area were significantly increased in the chronic renal failure patients: 341·9 vs 211·8 mL min−1; and 69·3 and 35·5 L. There were no differences in intrinsic clearance or apparent volume of distribution at steady state for unbound drug between the two patient groups.